HER3 expression is enhanced during progression of lung adenocarcinoma without EGFR mutation from stage 0 to IA1

BACKGROUND: Activating EGFR mutations, HER2, and HER3 are implicated in lung cancer; however, with the exception of EGFR gene amplification in lung adenocarcinoma harboring EGFR mutations, their involvement in disease progression during the early stages is poorly understood. In this paper, we focuse...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thorac Cancer
Hlavní autoři: Kumagai, Toru, Tomita, Yasuhiko, Nakatsuka, Shin‐ichi, Kimura, Madoka, Kunimasa, Kei, Inoue, Takako, Tamiya, Motohiro, Nishino, Kazumi, Susaki, Yoshiyuki, Kusu, Takashi, Tokunaga, Toshiteru, Okami, Jiro, Higashiyama, Masahiko, Imamura, Fumio
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons Australia, Ltd 2018
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5879050/
https://ncbi.nlm.nih.gov/pubmed/29473311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12609
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky